Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00072462




Registration number
NCT00072462
Ethics application status
Date submitted
4/11/2003
Date registered
6/11/2003
Date last updated
19/09/2024

Titles & IDs
Public title
Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
Scientific title
International Breast Cancer Intervention Study II (IBIS-II) (DCIS)
Secondary ID [1] 0 0
EU-20226
Secondary ID [2] 0 0
ISRCTN37546358
Universal Trial Number (UTN)
Trial acronym
IBIS-II DCIS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast
Cancer 0 0 0 0
Cervical (cervix)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - tamoxifen citrate
Treatment: Drugs - Anastrozole

Active comparator: Anastrozole -

Active comparator: Tamoxifen -


Treatment: Drugs: tamoxifen citrate
Tamoxifen 20mg + Anastrozole placebo

Treatment: Drugs: Anastrozole
Anastrozole 1mg + Tamoxifen placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Development of histologically confirmed breast cancer, both invasive and non-invasive with median follow-up at 5 years
Timepoint [1] 0 0
2 years
Secondary outcome [1] 0 0
To examine the effect of tamoxifen vs anastrozole on breast cancer mortality
Timepoint [1] 0 0
7 years

Eligibility
Key inclusion criteria
DISEASE CHARACTERISTICS:

* Diagnosis of ductal carcinoma in situ within the past 6 months

* Locally excised with tumor-free margins at least 1 mm
* Hormone receptor status:

* Estrogen or progesterone receptor positive

* Equal to or greater than 5% positive cells

PATIENT CHARACTERISTICS:

Age

* 40 to 70

Sex

* Female

Menopausal status

* Postmenopausal, defined as meeting at least 1 of the following criteria:

* Over age 60
* Prior bilateral oophorectomy
* Age 60 or under with a uterus AND amenorrhea for at least the past 12 months
* Age 60 or under without a uterus AND follicle-stimulating hormone greater than 20 IU/L

Performance status

* Not specified

Life expectancy

* At least 10 years

Hematopoietic

* Not specified

Hepatic

* Not specified

Renal

* Not specified

Cardiovascular

* No prior deep vein thrombosis
* No prior transient ischemic attack
* No prior cerebrovascular accident

Pulmonary

* No prior pulmonary embolism

Other

* No unexplained postmenopausal bleeding
* No other cancer within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
* No other concurrent medical condition that would preclude study therapy, place the patient at unusual risk, or confound study results
* No evidence of osteoporosis
* Fragility fractures within the spine allowed if T-score level is greater than -4 and consist of no more than 2 fractures
* Psychologically and physically suitable for 5 years of study therapy

PRIOR CONCURRENT THERAPY:

Biologic therapy

* Not specified

Chemotherapy

* Not specified

Endocrine therapy

* No prior or concurrent tamoxifen use lasting more than 6 months unless treatment was completed more than 5 years ago. Women in IBIS-I can join if off trial therapy for at least 5 years.
* No prior or concurrent raloxifene use lasting more than 6 months unless treatment was completed more than 5 years ago.
* No other prior or concurrent selective estrogen-receptor modulator use lasting more than 6 months unless treatment was completed more than 5 years ago
* No concurrent systemic estrogen-based hormone replacement therapy, including vaginal estrogen preparations

Radiotherapy

* Not specified

Surgery

* See Disease Characteristics
* No prior mastectomy
* No planned prophylactic mastectomy

Other

* At least 3 months since prior unapproved or experimental agents
* No concurrent anticoagulants
Minimum age
40 Years
Maximum age
70 Years
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/09/2003
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
31/05/2021
Sample size
Target
Accrual to date
Final
2980
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Australia - Newcastle
Recruitment postcode(s) [1] 0 0
- Newcastle
Recruitment outside Australia
Country [1] 0 0
Austria
State/province [1] 0 0
Vienna
Country [2] 0 0
Belgium
State/province [2] 0 0
Leuven
Country [3] 0 0
Chile
State/province [3] 0 0
Santiago
Country [4] 0 0
France
State/province [4] 0 0
Avignon
Country [5] 0 0
France
State/province [5] 0 0
Bordeaux
Country [6] 0 0
France
State/province [6] 0 0
Brest
Country [7] 0 0
France
State/province [7] 0 0
Caen
Country [8] 0 0
France
State/province [8] 0 0
Clermont-Ferrand
Country [9] 0 0
France
State/province [9] 0 0
Dijon
Country [10] 0 0
France
State/province [10] 0 0
Lagny Sur Marne
Country [11] 0 0
France
State/province [11] 0 0
Le Havre
Country [12] 0 0
France
State/province [12] 0 0
Lille
Country [13] 0 0
France
State/province [13] 0 0
Limoges
Country [14] 0 0
France
State/province [14] 0 0
Mulhouse
Country [15] 0 0
France
State/province [15] 0 0
Nantes
Country [16] 0 0
France
State/province [16] 0 0
Perpignan
Country [17] 0 0
France
State/province [17] 0 0
Reims
Country [18] 0 0
France
State/province [18] 0 0
Rennes
Country [19] 0 0
France
State/province [19] 0 0
Rouen
Country [20] 0 0
France
State/province [20] 0 0
Toulouse
Country [21] 0 0
France
State/province [21] 0 0
Villejuif
Country [22] 0 0
Germany
State/province [22] 0 0
Neu-Isenburg
Country [23] 0 0
Hungary
State/province [23] 0 0
Szeged
Country [24] 0 0
Ireland
State/province [24] 0 0
Cork
Country [25] 0 0
Ireland
State/province [25] 0 0
Dublin
Country [26] 0 0
Ireland
State/province [26] 0 0
Galway
Country [27] 0 0
Ireland
State/province [27] 0 0
Limerick
Country [28] 0 0
Ireland
State/province [28] 0 0
Sligo
Country [29] 0 0
Ireland
State/province [29] 0 0
Tallaght
Country [30] 0 0
Italy
State/province [30] 0 0
Milan
Country [31] 0 0
Malta
State/province [31] 0 0
Floriana
Country [32] 0 0
Sweden
State/province [32] 0 0
Lund
Country [33] 0 0
Switzerland
State/province [33] 0 0
(St. Gallen)
Country [34] 0 0
Switzerland
State/province [34] 0 0
Bern
Country [35] 0 0
Switzerland
State/province [35] 0 0
Geneva
Country [36] 0 0
Switzerland
State/province [36] 0 0
Lausanne
Country [37] 0 0
Switzerland
State/province [37] 0 0
Luzern
Country [38] 0 0
Switzerland
State/province [38] 0 0
Mendrisio
Country [39] 0 0
Switzerland
State/province [39] 0 0
St. Gallen
Country [40] 0 0
Switzerland
State/province [40] 0 0
Thun
Country [41] 0 0
Turkey
State/province [41] 0 0
Istanbul
Country [42] 0 0
United Kingdom
State/province [42] 0 0
England
Country [43] 0 0
United Kingdom
State/province [43] 0 0
Northern Ireland
Country [44] 0 0
United Kingdom
State/province [44] 0 0
Please Select
Country [45] 0 0
United Kingdom
State/province [45] 0 0
Scotland
Country [46] 0 0
United Kingdom
State/province [46] 0 0
Wales
Country [47] 0 0
United Kingdom
State/province [47] 0 0
Aberdeen
Country [48] 0 0
United Kingdom
State/province [48] 0 0
Ashton under Lyne
Country [49] 0 0
United Kingdom
State/province [49] 0 0
Bolton
Country [50] 0 0
United Kingdom
State/province [50] 0 0
Bournemouth
Country [51] 0 0
United Kingdom
State/province [51] 0 0
Bradford
Country [52] 0 0
United Kingdom
State/province [52] 0 0
Brighton
Country [53] 0 0
United Kingdom
State/province [53] 0 0
Bristol
Country [54] 0 0
United Kingdom
State/province [54] 0 0
Burton
Country [55] 0 0
United Kingdom
State/province [55] 0 0
Cheltenham
Country [56] 0 0
United Kingdom
State/province [56] 0 0
Chester
Country [57] 0 0
United Kingdom
State/province [57] 0 0
Derby
Country [58] 0 0
United Kingdom
State/province [58] 0 0
Epping
Country [59] 0 0
United Kingdom
State/province [59] 0 0
Exeter
Country [60] 0 0
United Kingdom
State/province [60] 0 0
Frimley
Country [61] 0 0
United Kingdom
State/province [61] 0 0
Grantham
Country [62] 0 0
United Kingdom
State/province [62] 0 0
Hastings
Country [63] 0 0
United Kingdom
State/province [63] 0 0
Huddersfield
Country [64] 0 0
United Kingdom
State/province [64] 0 0
Hull
Country [65] 0 0
United Kingdom
State/province [65] 0 0
Keighley
Country [66] 0 0
United Kingdom
State/province [66] 0 0
Leeds
Country [67] 0 0
United Kingdom
State/province [67] 0 0
Lincoln
Country [68] 0 0
United Kingdom
State/province [68] 0 0
Plymouth
Country [69] 0 0
United Kingdom
State/province [69] 0 0
Portsmouth
Country [70] 0 0
United Kingdom
State/province [70] 0 0
Scarborough
Country [71] 0 0
United Kingdom
State/province [71] 0 0
Sheffield
Country [72] 0 0
United Kingdom
State/province [72] 0 0
Stafford
Country [73] 0 0
United Kingdom
State/province [73] 0 0
Swansea
Country [74] 0 0
United Kingdom
State/province [74] 0 0
Truro
Country [75] 0 0
United Kingdom
State/province [75] 0 0
Wakefield
Country [76] 0 0
United Kingdom
State/province [76] 0 0
Welwyn
Country [77] 0 0
United Kingdom
State/province [77] 0 0
Wishaw
Country [78] 0 0
United Kingdom
State/province [78] 0 0
Worthing
Country [79] 0 0
United Kingdom
State/province [79] 0 0
Yeovil
Country [80] 0 0
United Kingdom
State/province [80] 0 0
York

Funding & Sponsors
Primary sponsor type
Other
Name
Queen Mary University of London
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Cancer Research UK
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using either tamoxifen or anastrozole may fight breast cancer by blocking the use of estrogen. It is not yet known whether tamoxifen is more effective than anastrozole in preventing breast cancer after surgery for ductal carcinoma in situ.

PURPOSE: This randomized phase III trial is studying how well adjuvant tamoxifen works compared to anastrozole in treating postmenopausal women who have undergone surgery to remove ductal carcinoma in situ.
Trial website
https://clinicaltrials.gov/study/NCT00072462
Trial related presentations / publications
Juraskova I, Butow P, Lopez A, Seccombe M, Coates A, Boyle F, McCarthy N, Reaby L, Forbes JF. Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS). Health Expect. 2008 Sep;11(3):252-62. doi: 10.1111/j.1369-7625.2008.00498.x.
Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11.
Sestak I, Smith SG, Howell A, Forbes JF, Cuzick J. Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II. Ann Oncol. 2018 Feb 1;29(2):504-509. doi: 10.1093/annonc/mdx713.
Public notes

Contacts
Principal investigator
Name 0 0
Jack Cuzick, PhD
Address 0 0
Queen Mary University of London
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00072462